The Justice Department's Office of the Inspector General announced Monday it is opening a formal review of the Drug Enforcement Administration's use of so-called "controlled delivery" operations involving fentanyl — a practice in which federal agents knowingly allowed shipments of the lethal drug to proceed to their destinations rather than seize them, on the calculated bet that patience would yield a larger prosecution.

The core question the OIG will attempt to answer is a brutal one: did DEA personnel have advance knowledge of specific fentanyl deliveries — shipments that ultimately ended up on streets, and potentially in the arms of people who died — and make a deliberate operational decision not to intervene? If the answer is yes, the follow-up question is whether any of those decisions were authorized, documented, and supervised as the law requires, or whether agents were freelancing in the shadows of a policy that has never been publicly debated.

Controlled delivery is not new, and it is not inherently illegal. Federal law enforcement has used the tactic for decades against heroin, cocaine, and arms networks, and courts have generally upheld properly supervised operations. The difference with fentanyl is a matter of lethality that is almost impossible to overstate. A few milligrams — an amount that would barely register on a postal scale — is a lethal dose. Allowing a fentanyl shipment to "walk" is not analogous to letting a cocaine brick reach a warehouse. It is, in the worst-case reading, making a prosecutorial wager with other people's lives as the stake.

The inquiry arrives against a backdrop of sustained political and public pressure over the fentanyl crisis, which the CDC has documented as the leading driver of overdose deaths in the United States, with synthetic opioids accounting for the vast majority of the more than 74,000 opioid-involved overdose deaths recorded in the most recent full reporting year. Against that scale of death, the revelation that a federal agency may have watched shipments move and said nothing carries a charge that goes well beyond bureaucratic misconduct.

New Mexico features in the inquiry's geographic scope — a state that has long posted some of the highest overdose death rates in the country, a grim distinction that reflects both its position along trafficking corridors and the poverty and social dislocation that make drug markets harder to escape. Whether specific deaths in New Mexico are traceable to shipments DEA monitored and did not stop is precisely the kind of question the OIG will need to answer with documented case files rather than inference.

The DEA has not publicly disputed the existence of controlled delivery operations involving fentanyl, which puts the agency in the uncomfortable position of defending a tactic whose logic — disrupt networks at the top, not the edges — sounds rational in a conference room and catastrophic when measured against a coroner's log. The agency's standard defense of such operations emphasizes that dismantling supply networks saves more lives in aggregate than intercepting individual shipments. That argument deserves to be stress-tested against actual data, which is exactly what the OIG review is positioned to do — if it is given genuine access to case files and not managed toward a pre-cooked conclusion.

There is a darker institutional question threading through all of this that official Washington has little appetite to examine directly. The DEA's budget, headcount, and institutional prestige are all tied to its ability to produce high-profile takedowns — the press conference with the seized bricks and the indicted cartel figures. Controlled deliveries are one tool for manufacturing those moments. That incentive structure does not make every controlled delivery corrupt, but it does mean the agency has a built-in motive to let things ride longer than the public interest strictly requires. An honest inspector general investigation would look not just at individual operations but at whether the performance metrics DEA uses internally create pressure to prioritize prosecutorial spectacle over harm reduction.

The OIG has produced consequential reports before — its 2019 review of the FBI's handling of FISA applications in the Carter Page investigation reshaped public understanding of that episode in ways that cut against multiple competing narratives simultaneously. Whether this review reaches that standard, or becomes a document carefully shaped to reassure rather than reveal, will depend on access, independence, and the willingness of career investigators to follow the case files wherever they lead. The families of fentanyl victims in New Mexico and elsewhere are owed something more than a report that concludes, after eighteen months and considerable expense, that procedures were generally followed.